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Introduction
Glutamine supplementation for critically ill patients has
become controversial after trials showing a negative
effect on clinical outcome. However, in addition to
patients with very low glutamine levels there are
patients with very high levels and most likely supple-
mentation needs to be individualised to the patients
with low levels. Unfortunately no clinically acceptable
bedside analysis for glutamine is available.
Objectives
In this study, a point-of-care instrument developed for
measuring glutamine levels in cell cultures was validated
for bedside use in the ICU setting and compared with a
standard HPLC technique to measure plasma glutamine.
The aim was to make evaluations for absolute measure-
ments and for clinical screening purposes.
Methods
Blood samples were obtained during ICU stay from one
hundred adult ICU patients 3-5 days apart as long as
patients were treated in the ICU. Patients younger than
18 years, not given consent or re-admitted to the ICU
were excluded. Each sample was divided into 3 aliquots;
for analyses of plasma and whole blood glutamine by the
point-of-care (POC) instrument (Bioprofile Basic, Nova
Biomedical, Waltham, MA, USA) and for analysis of
plasma glutamine concentration by the gold standard
HPLC technique. The analyses were compared with
regression analyses and Bland-Altman plots.
Results
The initial sample of all subject (n = 100) showed a good
correlation between plasma and whole blood analyses
on the POC when corrected for hematocrit (r = 0.99,
p < 0.001). Comparison of plasma glutamine measured on
the POC and HPLC gave a good correlation (r = 0.98, p <
0.001) but Bland-Altman analyses revealed a line of iden-
tity of -222 µmol /L and lines of agreement (2xSD) of 55
and -499 µmol /L. However, after pragmatic adjustments
for the constant bias (222 µmol /L) and hematocrit (0.30),
POC analyses of whole blood compared with HPLC
plasma analyses (all samples; n = 316) showed a line of
identity of -34 µmol /L and limits of agreement between
288 and -355 µmol /L.
Conclusions
When compared to the HPLC gold standard, in particular
the bias of -222 µmol /L, indicates that the point-of-care
instrument is not suitable for absolute plasma glutamine
concentration measurements. For screening purposes to
identify patients with hypoglutaminemia and hypergluta-
minemia the instrument may be useful when adjusted for
this constant bias. Identification of subjects with hypoglu-
taminemia for supplementation was safe. The point-
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